Catabasis Pharmaceuticals
| Region | Nordamerika |
| ISIN | US14875P2065 |
| Sektor | Biotechnologie |
| Website | https://www.catabasis.com/ |
At Catabasis Pharmaceuticals, our mission is to bring hope and life-changing therapies to patients and their families. Our lead program is edasalonexent, an NF-kB inhibitor in development for the treatment of Duchenne muscular dystrophy. Our global Phase 3 PolarisDMD trial is currently enrolling boys affected by Duchenne. For more information on edasalonexent and our Phase 3 PolarisDMD trial, please visit www.catabasis.com or www.twitter.com/catabasispharma.
| Titel | Autor | Datum |
|---|---|---|
|
Der Tenbagger-Kandidat für 2020!
|
sharedeals | vor ungefähr 5 Jahren |
|
Der heißeste Buyout-Kandidat des Jahres!
2 Kommentare |
sharedeals | vor ungefähr 6 Jahren |
| Titel | Datum |
|---|---|
| MISC sinks into red for the first time in more than two years as provisions hurt | vor ungefähr 2 Monaten |
|
The Recipient Copy Deadline for 1099-B, 1099-S, and 1099-MISC is Approaching Fast: TaxBandits Makes Distribution Easy
Businesses must meet the February 18, 2025 deadline to furnish recipient copies of Forms 1099-B, ... |
vor ungefähr 3 Monaten |
| SBM Offshore finalizes asset swap with MISC Berhad | vor ungefähr 3 Monaten |
| SBM Offshore and MISC wrap up FPSO stake swap | vor ungefähr 3 Monaten |
|
SBM Offshore N.V.: SBM Offshore completes the Share Purchase Agreements with MISC Berhad
Amsterdam, January 31, 2025 SBM Offshore confirms it has completed the transactions related to t... |
vor ungefähr 3 Monaten |
| Diese Aktien könnten Dich auch interessieren | |
|---|---|
| Cannabis Wheaton Income (2 Artikel) | |
| BYD Company (1 Artikel) | |
| CBLT (1 Artikel) | |
| Celgene (1 Artikel) | |
| Alle anzeigen | |